IP Library › Granted Patent US 12,606,792
Granted Patent B2
US 12,606,792 · App. 18/455,388 · Granted Apr 21, 2026

Cell concentration methods and devices for use in automated bioreactors

Inventors: Joseph O'Connor (Walkersville, MD); Erika McAfee (Walkersville, MD); Samatha Bandapalle (Walkersville, MD); Yaling Shi (Walkersville, MD); Eytan Abraham (Walkersville, MD)
Assignee: LONZA WALKERSVILLE, INC.
C12M47/02B01D61/145B01D71/34B01D71/421B01D71/5211B01L3/502715B01L3/50273C12M29/04C12M41/26C12M41/30C12M41/48B01D2311/2523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,792
App. No.
18/455,388
Granted
Apr 21, 2026
Kind
B2
Abstract

The present disclosure provides cassettes for use in automated cell engineering systems that include cell concentration filters for reducing fluid volume of a cell sample during or following automated processing. The disclosure also provides methods of concentrating a cell population, as well as automated cell engineering systems that can utilize the cassettes and carry out the methods.

Claims (47)

1 . A cassette for use in an automated cell engineering system, comprising:

(a) a cell culture chamber;

(b) a peristaltic pump fluidly connected to the cell culture chamber;

(c) a tangential flow filter fluidly connected to the peristaltic pump, wherein the peristaltic pump provides a retentate flow to the tangential flow filter and wherein a permeate flow of the tangential flow filter is controlled by a flow controller;

(d) a satellite volume connected to the tangential flow filter, wherein the cassette defines the satellite volume;

(e) a fluidics pathway for recirculating the retentate flow from the satellite volume back through the tangential flow filter;

(f) a fixed volume waste collection chamber fluidly connected to the tangential flow filter and configured to stop a removal of permeate flow once the fixed volume waste collection chamber reaches a fixed volume; and

(g) a cellular sample output fluidly connected to the tangential flow filter.

2 . The cassette of claim 1 , wherein the tangential flow filter has a pore size of about 0.40 mm to about 0.80 mm and a fiber diameter of about 0.5 mm to about 0.9 mm.

3 . The cassette of claim 1 , wherein the cell culture chamber is maintained at a temperature to allow for cell proliferation and growth.

4 . The cassette of claim 1 , wherein the tangential flow filter comprises a polymer selected from the group consisting of poly(ether sulfone), poly(acrylonitrile) and poly(vinylidene difluoride).

5 . The cassette of claim 1 , further comprising a pH sensor, a glucose sensor, an oxygen sensor, a carbon dioxide sensor, and/or an optical density sensor.

6 . The cassette of claim 1 , further comprising one or more sampling ports.

7 . The cassette of claim 1 , wherein the flow controller is a flow restrictor.

8 . The cassette of claim 1 , wherein the flow controller is an additional pump.

9 . The cassette of claim 1 , wherein the flow controller is a system having a plurality of tubing to restrict or increase an amount and rate of permeate flow.

10 . The cassette of claim 1 , wherein the tangential flow filter is angled more than 0° and less than 20° relative to horizontal such that an exit end of the tangential flow filter is disposed vertically above an input end of the tangential flow filter.

11 . An automated cell engineering system, comprising:

(a) an enclosable housing;

(b) a cassette contained within the enclosable housing, the cassette comprising:

i. a cell culture chamber;

ii. a peristaltic pump fluidly connected to the cell culture chamber;

iii. a tangential flow filter fluidly connected to the peristaltic pump, wherein the peristaltic pump provides a retentate flow to the tangential flow filter and wherein a permeate flow of the tangential flow filter is controlled by a flow controller; and

iv. a cellular sample output fluidly connected to the tangential flow filter;

(c) a user interface for receiving input from a user;

(d) a satellite volume for receiving the retentate flow from the tangential flow filter, the satellite volume disposed within the enclosable housing wherein the cassette defines the satellite volume;

(e) a fixed volume waste collection chamber fluidly connected to the tangential flow filter and configured to stop a removal of permeate flow once the fixed volume waste collection chamber reaches a fixed volume; and

(f) a fluidics pathway for recirculating the retentate flow from the satellite volume back through the tangential flow filter.

12 . The automated cell engineering system of claim 11 , wherein the tangential flow filter has a pore size of about 0.40 mm to about 0.80 mm and a fiber diameter of about 0.5 mm to about 0.9 mm.

13 . The automated cell engineering system of claim 11 , wherein the cell culture chamber is maintained at a temperature to allow for cell proliferation and growth.

14 . The automated cell engineering system of claim 11 , wherein the tangential flow filter comprises a polymer selected from the group consisting of poly(ether sulfone), poly(acrylonitrile) and poly(vinylidene difluoride).

15 . The automated cell engineering system of claim 11 , wherein the cassette further comprises one or more sampling ports.

16 . The automated cell engineering system of claim 11 , wherein the flow controller is a flow restrictor.

17 . The automated cell engineering system of claim 11 , wherein the flow controller is an additional pump.

18 . The automated cell engineering system of claim 11 , wherein the flow controller is a system having a plurality of tubing to restrict or increase an amount and rate of permeate flow.

19 . The automated cell engineering system of claim 11 , wherein the tangential flow filter is angled more than 0° and less than 20° relative to horizontal such that an exit end of the tangential flow filter is disposed vertically above an input end of the tangential flow filter.

20 . The automated cell engineering system of claim 11 , further comprising a pH sensor, a glucose sensor, an oxygen sensor, a carbon dioxide sensor, and/or an optical density sensor.

21 . The automated cell engineering system of claim 11 , wherein the fixed volume waste collection chamber is disposed within the enclosable housing.

22 . An automated cell engineering system, comprising:

(a) an enclosable housing;

(b) a cassette contained within the enclosable housing, the cassette comprising:

i. a cell culture chamber;

ii. a pump fluidly connected to the cell culture chamber;

iii. a tangential flow filter fluidly connected to the pump, wherein the pump provides a retentate flow to the tangential flow filter and wherein a permeate flow of the tangential flow filter is controlled by a flow controller, wherein the tangential flow filter is angled more than 0° and less than 20° relative to horizontal such that an exit end of the tangential flow filter is disposed vertically above an input end of the tangential flow filter; and

iv. a cellular sample output fluidly connected to the tangential flow filter;

(c) a user interface for receiving input from a user; and

(d) a satellite volume for receiving the retentate flow from the tangential flow filter, the satellite volume disposed within the enclosable housing, wherein the cassette defines the satellite volume.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2026
From: LONZA WALKERSVILLE, INC.
To: OCTANE BIOTECH INC.
Reel/Frame 075379/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: O'CONNOR, JOSEPH; MCAFEE, ERIKA; BANDAPALLE, SAMATHA; SHI, YALING; ABRAHAM, EYTAN
To: LONZA WALKERSVILLE, INC.
Reel/Frame 064702/0390 →
Continuity (3)
Division 16782181 · Feb 5, 2020
Provisional Application 62803219 · Feb 8, 2019
Related Publication 20230407234A1 · Dec 21, 2023
References Cited (222)
US 4642120A · Nevo et al. · 1987 [cited by applicant]
US 4939151A · Bacehowski et al. · 1990 [cited by applicant]
US 5041138A · Vacanti et al. · 1991 [cited by applicant]
US 5081036A · Familletti · 1992 [cited by applicant]
US 5240854A · Berry et al. · 1993 [cited by applicant]
US 5246699A · Debre et al. · 1993 [cited by applicant]
US 5424209A · Kearney · 1995 [cited by applicant]
US 5478479A · Herrig · 1995 [cited by applicant]
US 5549134A · Browne et al. · 1996 [cited by applicant]
US 5688687A · Palsson et al. · 1997 [cited by applicant]
US 5728581A · Schwartz et al. · 1998 [cited by applicant]
US 5786207A · Katz et al. · 1998 [cited by applicant]
US 5792603A · Dunkelman et al. · 1998 [cited by applicant]
US 5827729A · Naughton et al. · 1998 [cited by applicant]
US 5842477A · Naughton et al. · 1998 [cited by applicant]
US 5846828A · Peterson et al. · 1998 [cited by applicant]
US 5882929A · Fofonoff et al. · 1999 [cited by applicant]
US 5891455A · Sittinger et al. · 1999 [cited by applicant]
US 5902741A · Purchio et al. · 1999 [cited by applicant]
US 5906934A · Grande et al. · 1999 [cited by applicant]
US 5922604A · Stapleton et al. · 1999 [cited by applicant]
US 5928936A · Ingram · 1999 [cited by applicant]
US 5985653A · Armstrong et al. · 1999 [cited by applicant]
US 5989913A · Anderson et al. · 1999 [cited by applicant]
US 5994129A · Armstrong et al. · 1999 [cited by applicant]
US 6048721A · Armstrong et al. · 2000 [cited by applicant]
US 6048722A · Farb et al. · 2000 [cited by applicant]
US 6060306A · Flatt et al. · 2000 [cited by applicant]
US 6096532A · Armstrong et al. · 2000 [cited by applicant]
US 6121042A · Peterson et al. · 2000 [cited by applicant]
US 6123655A · Fell · 2000 [cited by applicant]
US 6197575B1 · Griffith et al. · 2001 [cited by applicant]
US 6214574B1 · Kopf · 2001 [cited by applicant]
US 6228635B1 · Armstrong et al. · 2001 [cited by applicant]
US 6238908B1 · Armstrong et al. · 2001 [cited by applicant]
US 6297046B1 · Smith et al. · 2001 [cited by applicant]
US 6323146B1 · Pugh et al. · 2001 [cited by applicant]
US 6402941B1 · Lucido et al. · 2002 [cited by applicant]
US 7348175B2 · Vilendrer et al. · 2008 [cited by applicant]
US 7906323B2 · Cannon et al. · 2011 [cited by applicant]
US 8492140B2 · Smith et al. · 2013 [cited by applicant]
US 8727132B2 · Miltenyi et al. · 2014 [cited by applicant]
US 9499780B2 · Smith et al. · 2016 [cited by applicant]
US 9534195B2 · Smith et al. · 2017 [cited by applicant]
US 9629877B2 · Cooper et al. · 2017 [cited by applicant]
US 9701932B2 · Smith et al. · 2017 [cited by applicant]
US 9783768B2 · Larcher et al. · 2017 [cited by applicant]
US 10131876B2 · Kaiser et al. · 2018 [cited by applicant]
US 10253316B2 · Masquelier et al. · 2019 [cited by applicant]
US 10273300B2 · Bedoya et al. · 2019 [cited by applicant]
US 11208626B2 · Mason et al. · 2021 [cited by applicant]
US 11773365B2 · O'Connor · 2023 [cited by examiner]
US 20010021529A1 · Takagi · 2001 [cited by applicant]
US 20010043918A1 · Masini et al. · 2001 [cited by applicant]
US 20020009797A1 · Wolf et al. · 2002 [cited by applicant]
US 20020009803A1 · Vajta · 2002 [cited by applicant]
US 20020025547A1 · Rao · 2002 [cited by applicant]
US 20020037580A1 · Schoeb · 2002 [cited by applicant]
US 20020146816A1 · Vellinger · 2002 [cited by examiner]
US 20020155487A1 · Greenberger et al. · 2002 [cited by applicant]
US 20020179525A1 · Shaffer et al. · 2002 [cited by applicant]
US 20030032071A1 · Wang et al. · 2003 [cited by applicant]
US 20030040104A1 · Barbera-Guillem · 2003 [cited by applicant]
US 20030054335A1 · Taya et al. · 2003 [cited by applicant]
US 20030159946A1 · Eden et al. · 2003 [cited by applicant]
US 20030215935A1 · Coon · 2003 [cited by applicant]
US 20040048364A1 · Trosch · 2004 [cited by applicant]
US 20050064465A1 · Dettloff et al. · 2005 [cited by applicant]
US 20050130297A1 · Sarem et al. · 2005 [cited by applicant]
US 20050186671A1 · Cannon et al. · 2005 [cited by applicant]
US 20110207209A1 · Hammons · 2011 [cited by examiner]
US 20130270165A1 · Shevitz · 2013 [cited by examiner]
US 20140051167A1 · Nankervis · 2014 [cited by examiner]
US 20140093952A1 · Serway · 2014 [cited by applicant]
US 20150247114A1 · Gebauer · 2015 [cited by applicant]
US 20150344844A1 · Better et al. · 2015 [cited by applicant]
US 20160122782A1 · Crisman et al. · 2016 [cited by applicant]
US 20170037369A1 · Ramsborg et al. · 2017 [cited by applicant]
US 20170051252A1 · Morgan et al. · 2017 [cited by applicant]
US 20190169572A1 · Shi et al. · 2019 [cited by applicant]
US 20190211294A1 · Karnieli · 2019 [cited by applicant]
US 20200009614A1 · McNaughton · 2020 [cited by examiner]
AU 2002324169A1 · 2003 [cited by applicant]
DE 4021123A1 · 1991 [cited by applicant]
EP 0248675A1 · 1987 [cited by applicant]
GB 1356794A · 1974 [cited by applicant]
JP 2119772A · 1990 [cited by applicant]
JP 2174848A · 1990 [cited by applicant]
JP 3500847A · 1991 [cited by applicant]
JP 5503418A · 1993 [cited by applicant]
JP 654678A · 1994 [cited by applicant]
JP 6261736A · 1994 [cited by applicant]
JP 7501206A · 1995 [cited by applicant]
JP H0856646A · 1996 [cited by applicant]
JP H11507229A · 1999 [cited by applicant]
JP 2001275659A · 2001 [cited by applicant]
JP 2001517428A · 2001 [cited by applicant]
JP 2002500004A · 2002 [cited by applicant]
JP 2013517771A · 2013 [cited by applicant]
KR 20000023786U · 2001 [cited by applicant]
WO 9105849A1 · 1991 [cited by applicant]
WO 9303142A1 · 1993 [cited by applicant]
WO 199712960A2 · 1997 [cited by applicant]
WO 9933951A1 · 1999 [cited by applicant]
WO 9947922A2 · 1999 [cited by applicant]
WO 2000046349A1 · 2000 [cited by applicant]
WO 0102030A2 · 2001 [cited by applicant]
WO 2001000783A2 · 2001 [cited by applicant]
WO 2002028996A1 · 2002 [cited by applicant]
WO 02088295A1 · 2002 [cited by applicant]
WO 03022985A2 · 2003 [cited by applicant]
WO 03087292A2 · 2003 [cited by applicant]
WO 2003085101A1 · 2003 [cited by applicant]
WO 2015162211A1 · 2015 [cited by applicant]
WO 2015175679A2 · 2015 [cited by applicant]
WO 2016069993A1 · 2016 [cited by applicant]
WO 2016118780A1 · 2016 [cited by applicant]
WO 2016168275A1 · 2016 [cited by applicant]
WO 2017068425A1 · 2017 [cited by applicant]
WO 2018015561A1 · 2018 [cited by applicant]
WO 2018136566A1 · 2018 [cited by applicant]
Cheng, et al. “Effects of gas slugs and inclination angle on the ultrafiltration flux in tubular membrane module” Journal of Membrane Science 158 223-234 (Year: 1999). [cited by examiner]
Oxford Language Dictionary Definition (Year: 2025). [cited by examiner]
Viktor Shkolnikov et al. A self-priming, roller-free, miniature, peristaltic pump operable with a single, reciprocating actuator Sensors and Actuators A: Physical vol. 160, Issues 1-2, May 2010, pp. 141-146 (Year: 2010). [cited by examiner]
Andris et al., “Naïve T Cells are Resistant to Anergy Induction by Anti-CD3 Antibodies,” The Journal of Immunology (2004) 173(5):3201-3208. [cited by applicant]
Atkuri et al., “Culturing at atmospheric oxygen levels impacts lymphocyte function,” PNAS (2005) 102(10):3756-3759. [cited by applicant]
Austyn et al., “T cell activation by anti-CD3 antibodies: function of Fc receptors on B cell blasts, but not resting B cells, and CD18 on the responding T cells.” European Journal of Immunology (1987) 17(9):1329-1335. [cited by applicant]
Avgoustiniatos et al., “Commercially Available Gas-Permeable Cell Culture Bags May Not Prevent Anoxia in Cultured or Shipped Islets,” Transplant Proc. (2008) 40(2):395-400. [cited by applicant]
Baroja et al., “The anti-T cell monoclonal antibody 9.3 (Anti-CD28) provides a helper signal and bypasses the need for accessory cells in T Cell activation with immobilized anti-CD3 and mitogens,” Cellular Immunology (1… [cited by applicant]
Berdeja et al., “First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results,” Journal of Clinical Oncology (2017) 35(15):3010. [cited by applicant]
Bohnenkamp et al., “Bioprocess development for the cultivation of human T-lymphocytes in a clincal scale,” Cytotechnology (2002) 38:135-145. [cited by applicant]
Carpenter et al., “Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells,” The Journal of Immunology (2000) 165(11):6208-6213. [cited by applicant]
Ceuppens et al., “T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a inability to cross-link the T3-Ti complex,” The Journal of I… [cited by applicant]
Chai et al., “Immobilized anti-CD3 mAb induces anergy in murine naïve and memory CD4+ T cells in vitro.,” Int Immunol. (1997) 9(7):935-944. [cited by applicant]
Charron et al., “Monocyte:T cell interaction regulates human T cell activation through a CD28/CD46 crosstalk,” Immunol Cell Biol. (2015) 93(9):796-803. [cited by applicant]
Church et al., “Tumor-specific CD4 [cited by applicant]
Clavreul et al., “Interelationship between CD3 and CD28 pathways in a murine T cell thymoma,” Molecular Immunology (2000) 37(10):571-577. [cited by applicant]
Dudley et al., “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients,” J Immunother. (2003) 26(4):332-342. [cited by applicant]
Fathman et al., “Molecular mechanisms of CD4 [cited by applicant]
FDA, Available online at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf. [cited by applicant]
FDA, Regenerative Medicine Advanced Therapy Designation. (2017). Available at: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm. (Accessed: Aug. 8, 2017). [cited by applicant]
FDA, Sepax Cell Separation System and single use kits. (2011). Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/SubstantiallyEquivalent510kDeviceInformation/UCM27838… [cited by applicant]
Feldmann et al., “Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells,” J Immunol. (2012) 189(6):3249-3259. [cited by applicant]
Fleischer et al., “Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes,” Immunology (1996) 89(4):592-598. [cited by applicant]
Gottschalk et al., The hype, hope and reality of personalization. The Medicine Maker (2015) p. 38-41. [cited by applicant]
Greenwald et al., “The B7 Family Revised,” Annual Review of Immunology (2005) 23:515-548. [cited by applicant]
Grishagin, Ivan V., “Automatic cell counting with ImageJ,” Analytical Biochemistry (2015) 473:63-65. [cited by applicant]
Hammill et al., “Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors,” Journal for Immuno Therapy of Cancer (2015) 3(55):1-11. [cited by applicant]
Harding et al., “CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones,” Nature (1992) 356:607-609. [cited by applicant]
Hasegawa et al., “In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15-Binding CD4 T-C… [cited by applicant]
Hollyman et al., “Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy,” J Immunother. (2009) 32(2):169-180. [cited by applicant]
Ju et al., “A functional anti-human 4-1BB ligand monoclonal antibody that enhances proliferation of monocytes by reverse signaling of 4-1BBL,” Hybrid Hybridomics (2003) 22(5):333-338. [cited by applicant]
Kaiser et al., “Towards a commercial process for the manufacture of genetically modified T cells for therapy,” Cancer Gene Therapy (2015) 22:72-78. [cited by applicant]
Kalos et al., “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia,” Sci Transl Med. (2011) 3(95):1-21. [cited by applicant]
Kebriaei et al., “Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells,” The Journal of Clinical Investigation (2016) 126(9):3363-3376. [cited by applicant]
Kochenderfer et al., “Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor,” Journal… [cited by applicant]
Lafferty et al., “A new analysis of allogeneic interactions,” Aust J Exp Biol Med Sci. (1975) 53(1):27-42. [cited by applicant]
Laux et al., “Response Differences between Human CD4 [cited by applicant]
Ledbetter et al., “CD28 Ligation in T-cell Activation: Evidence for Two Signal Transduction Pathways,” Blood (1990) 75(7):1531-1539. [cited by applicant]
Levine et al., “Global Manufacturing of CAR T Cell Therapy,” Molecular: Therapy: Methods & Clinical Development (2017) 4:92-101. [cited by applicant]
Li et al., “Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation,” Journal of Translational Me… [cited by applicant]
Lock et al., “Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use,” Human Gene Therapy (2017) 28(10):914-925. [cited by applicant]
Locke et al., “Abstract CT019: Primary results from ZUMA-1: a pivotal trial axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL),” Cancer Research (2017) 77(13). [cited by applicant]
Locke et al., “Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma,” Molecular Therapy (2017) 25(1):285-295. [cited by applicant]
Lu et al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies,” Human Gene Therapy Methods (2016) 27(6):209-218. [cited by applicant]
Lu et al., “Automated dynamic fed-batch process and media optimization for high productivity cell culture process development,” Biotechnology and Bioengineering (2013) 110(1):191-205. [cited by applicant]
Lu et al., “Treatment of Patients with Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3,” Journal of Clinical Oncology (2017) 3… [cited by applicant]
Mock et al., “Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy,” Cytotherapy (2016) 18(8):1002-1011. [cited by applicant]
Morrissey et al., “End-to-End Cell Therapy Automation: An Immunotherapy Case Study,” BioPharm International (2017) 2:10-18. [cited by applicant]
Nilsson et al., “Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects,” Clinical and Vaccine Immunology (2008) 15(4):585-589. [cited by applicant]
Nociari et al., “A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity,” Journal of Immunological Methods (1998) 213(2):157-167. [cited by applicant]
Odeleye et al., “On the fluid dynamics of a laboratory scale single-use stirred bioreactor,” Chemical Engineering Science (2014) 111(100):299-312. [cited by applicant]
Reusch et al., “A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells,” MAbs (2015) 7(3):584-604. [cited by applicant]
Riddell et al., “Adoptive Therapy with Chimeric Antigen Receptor Modified T Cells of Defined Subset Composition,” Cancer J (2014) 20(2):141-144. [cited by applicant]
Riddell et al., “The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells,” Journal of Immunological Methods (1990) 128(2):189-201. [cited by applicant]
Romagnani, S, “Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease,” Int J Clin Lab Res (1991) 21(2):152-158. [cited by applicant]
Schwartz, RH, “A cell culture model for T lymphocyte clonal anergy,” Science (1990) 248(4961):1349-1356. [cited by applicant]
Schwartz, RH, “T cell anergy,” Annu Rev Immunol. (2003) 21:305-334. [cited by applicant]
Tangying et al., “A Rapid Cell Expansion Process for Production of Engineering Autologous CAR-T Cell Therapies,” Human Gene Therapy Methods (2016) 27(6):209-218. [cited by applicant]
Tax et al., “Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells,” Nature (1983) 304(5925):445:447. [cited by applicant]
Trainor et al., “Rethinking clinical delivery of adult stem cell therapies,” Nature Biotechnology (2014) 32:729-735. [cited by applicant]
Trickett et al., “T cell stimulation and expansion using anti-CD3/CD28 beads,” Journal of Immunological Methods (2003) 275(1-2):251-255. [cited by applicant]
Tuefferd et al., “HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients,” PLoS One (2007) 11:e1138. [cited by applicant]
Turtle et al., “CD19 CAR-T cells of defined CD4 [cited by applicant]
Vanseggelen et al., “Chimeric antigen receptor-engineered T cells as oncolytic virus carriers,” Molecular Therapy—Oncolytics (2015) 150014. [cited by applicant]
Verwilghen et al., “Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation,” Immunology (1991) 72:269-276. [cited by applicant]
Wang et al., “Clinical manufacturing of CAR T cells: foundation of a promising therapy” Mol. Ther.—Oncolytics (2016) 3:16015. [cited by applicant]
Wang et al., “Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies,” Cancer Gene Ther. (2015) 22(2):85-94. [cited by applicant]
Wauwe et al., “OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties,” The Journal of Immunology (1980) 124(6):2708-2713. [cited by applicant]
Wegener, C, “Cell Washing with the LOVO Cell Processing System,” BioProcess International (2014) p. 78. [cited by applicant]
Weiss et al., “T cell activation: differences in the signals required for IL 2 production by nonactivated and activated T cells,” J Immunol (1985) 135(6):3669-3673. [cited by applicant]
Wolf et al., “Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies,” European Journal of Immunology (1994) 24(6):1410-1417. [cited by applicant]
Yan et al., “HER2 expression status in diverse cancers: review of results from 37,992 patients,” Cancer Metastasis Rev (2015) 34:157-164. [cited by applicant]
Zhu et al., “CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype,” Immunobiology (2007) 109(11):4882-4889. [cited by applicant]
Konstantin B. Konstantinov “Monitoring and Control of the Physiological State of Cell Cultures” Biotechnology and Bioengineering, vol. 52, pp. 271-289 (1996) (Year: 1996). [cited by applicant]
Farndale “Pulsed Electromagnetic Fields Promote Collagen Production in Bone Marrow Fibroblasts via Athermal Mechanisms” Calcif Tissue Int (1985) 37:178-182. [cited by applicant]
Singapore Search Report for Sg 11202108473X dated May 9, 2023. [cited by applicant]
Aitken-Christie et al., Automation in Plant tissue culture—general introduction and overview, in Automation and Environmental Control in Plant Tissue Culture 757 (J. Aitken-Christie, T. Kozai & M. Lila Smith eds., 1995). [cited by applicant]
Apel et al., Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture, Chemie Ingenieur Technik (2013). [cited by applicant]
Armstrong et al., Clinical Systems for the Production of Cells and Tissues for Human Therapy, in Novel Therapeutics From Modern Biotechnology 221 (D.L. Oxender et al. eds., 1999). [cited by applicant]
Blaeschke et al., Induction of a Central Memory and Stem Cell Memory Phenotype in Functionally Active CD4+ and CD8+ CAR T Cells Produced in an Automated Good Manufacturing Practice System for the Treatment of CD19+ Acut… [cited by applicant]
Bousso, T-cell activation by dendritic cells in the lymph node: lessons from the movies, 8 Nature Reviews Immunology 675 (2008) (“Bousso 2008”). [cited by applicant]
Declaration from Mark Selker, Submitted in [cited by applicant]
Declaration from James C. Leung, Submitted in [cited by applicant]
Kempner et al., A Review of Cell Culture Automation, 7 Journal of the Association for Laboratory Automation 56 (2002) (“Kempner 2002”). [cited by applicant]
Koller et al., Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system, Bone Marrow Transplantation (1998) (“Koller 1998”). [cited by applicant]
Koller et al., Large-Scale Expansion of Human Stem and Progenitor Cells from Bone Marrow Mononuclear Cells in Continuous Perfusion Cultures, Blood (1993) (“Koller 1993A”). [cited by applicant]
Koller et al., Tissue Engineering: Reconstitution of Human Hematopoiesis Ex Vivo, Biotechnology and Bioengineering (1993) (“Koller 1993B”). [cited by applicant]
Kostov et al., Low-Cost Microbioreactor for High-Throughput Bioprocessing, 72 Biotechnology and Bioengineering, Feb. 5, 2001 (“Kostov 2001”). [cited by applicant]
Krug et al., A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor, Cancer Immunol Immunotherapy (2014) (“Krug 2014”). [cited by applicant]
Morse, Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc., Current Opinion in Molecule Therapeutics (1999) (“Morse 1999”). [cited by applicant]
Oh et al., Frequent Harvesting from Perfused Bone Marrow Cultures Results in Increased Overall Cell and Progenitor Expansion, Biotechnology and Bioengineering (1994). [cited by applicant]
Priesner et al., Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products, 27 Human Gene Therapy 10, 860-869 (2016). [cited by applicant]
Rosazza et al., Gene Electrotransfer: A Mechanistic Perspective, Current Gene Therapy (2016) (“Rosazza 2016”). [cited by applicant]
Shi et al., “Performance of Mammalian Cell Culture Bioreactor with a New Impeller Design” Biotechnology and Bioengineering, vol. 40, pp. 260-270 (1992). [cited by applicant]
Stiff et al., Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer, Blood (2000) (“Stiff 2000”). [cited by applicant]
Zhang et al., Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system, Drug Design, Development and Therapy (2018) (“Zhang 2018”). [cited by applicant]
Zhu et al., Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center, Cytotherapy (2018). [cited by applicant]
Luo et al., “Introduction of Food Biotechnology,” China Agricultural University Press 3:305-307 (2016). [cited by applicant]
Mao et al., “Downstream Processing of Bio-industry,” China Light Industry Press: 56-58 (1999). [cited by applicant]
Gu et al., “Use of Ion-exchange and Adsorption Resins in Pharmaceutical Industry”; China Medical Science Press: 49 (2008). [cited by applicant]
Office Action issued on Oct. 25, 2024, in corresponding CN Application No. 202080016817.1. [cited by applicant]